{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:09:52Z","timestamp":1791299392314,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T00:00:00Z","timestamp":1371686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Nausea and vomiting of pregnancy (NVP) is a common condition. The objective of this study was to evaluate the association between response to antiemetics in the treatment of NVP and genetic polymorphisms in the serotonin receptor subunit genes\n                      <jats:italic>HTR3A<\/jats:italic>\n                      and\n                      <jats:italic>HTR3B<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Pregnant women \u226518\u00a0years of age with NVP starting antiemetic therapy with promethazine, prochlorperazine, metoclopramide, or ondansetron at\u2009\u2264\u200916\u00a0weeks gestational age were eligible. The study recruited 29 women with complete data and sampling who returned for their one week follow-up and were genotyped for\n                      <jats:italic>HTR3A<\/jats:italic>\n                      and\n                      <jats:italic>HTR3B<\/jats:italic>\n                      polymorphisms. Severity of NVP was captured (using Pregnancy Unique Quantification of Emesis (PUQE) and Quality of Life (QOL) tools) upon enrollment and after one week of antiemetic therapy. These measures were correlated with pharmacogenetic variability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Subjects with genotype associated with high serotonin affinity of the 5-HT\n                      <jats:sub>3B<\/jats:sub>\n                      receptor (rs1176744, CC) required more antiemetic medications (p\u2009&lt;\u20090.001) than other subjects. Those with genotypes associated with increased expression of the 5-HT\n                      <jats:sub>3A<\/jats:sub>\n                      receptor subunit (rs1062613, CT or TT) had worse final PUQE scores (p = 0.01) than other subjects while rs3782025 variants carriers had significantly better initial (p = 0.02) and final (p = 0.02) PUQE scores than other subjects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>HTR3B<\/jats:italic>\n                      and\n                      <jats:italic>HTR3A<\/jats:italic>\n                      gene variants may contribute to variability in response to antiemetic therapy for NVP.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2393-13-132","type":"journal-article","created":{"date-parts":[[2013,6,20]],"date-time":"2013-06-20T04:14:30Z","timestamp":1371701670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study"],"prefix":"10.1186","volume":"13","author":[{"given":"Amalia S","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L","family":"Renbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine L","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel R","family":"Topletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Rouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,20]]},"reference":[{"issue":"3","key":"787_CR1","first-page":"106","volume":"22","author":"S Emelianova","year":"1999","unstructured":"Emelianova S, Mazzotta P, Einarson A, Koren G: Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. Clin Invest Med. 1999, 22 (3): 106-110.","journal-title":"Clin Invest Med"},{"key":"787_CR2","first-page":"245","volume":"43","author":"R Gadsby","year":"1993","unstructured":"Gadsby R, Barnie-Adshead A, Jagger C: A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract. 1993, 43: 245-248.","journal-title":"Br J Gen Pract"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0020-7292(00)00255-1","volume":"70","author":"P Mazzotta","year":"2000","unstructured":"Mazzotta P, Maltepe C, Navioz Y, Magee L, Koren G: Attitudes, management, and consequences of nausea and vomiting of pregnancy in the United States and Canada. Int J Gynaecol Obstetrics. 2000, 70: 359-365. 10.1016\/S0020-7292(00)00255-1.","journal-title":"Int J Gynaecol Obstetrics"},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1067\/mob.2002.122594","volume":"186","author":"F Miller","year":"2002","unstructured":"Miller F: Nausea and vomiting of pregnancy: the problem of perception\u2013is it really a disease?. Am J Obstet Gynecol. 2002, 186: S182-S183. 10.1067\/mob.2002.122594.","journal-title":"Am J Obstet Gynecol"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/01674820009075620","volume":"21","author":"P Mazzotta","year":"2000","unstructured":"Mazzotta P, Stewart D, Atanakovic G, Koren G, Magee L: Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with antiemetic therapy. J Psychosom Obstet Gynecol. 2000, 21: 129-136. 10.3109\/01674820009075620.","journal-title":"J Psychosom Obstet Gynecol"},{"key":"787_CR6","first-page":"1055","volume":"43","author":"P Mazzotta","year":"1997","unstructured":"Mazzotta P, Magee L, Koren G: Therapeutic abortions due to severe morning sickness. Unacceptable combination. Can Fam Physician. 1997, 43: 1055-1057.","journal-title":"Can Fam Physician"},{"issue":"5 Suppl Underst","key":"787_CR7","doi-asserted-by":"publisher","first-page":"S256","DOI":"10.1067\/mob.2002.122596","volume":"186","author":"LA Magee","year":"2002","unstructured":"Magee LA, Mazzotta P, Koren G: Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obstet Gynecol. 2002, 186 (5 Suppl Understanding): S256-S261.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"787_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1055\/s-2002-34469","volume":"19","author":"M Berkovitch","year":"2002","unstructured":"Berkovitch M, Mazzota P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, et al: Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol. 2002, 19 (6): 311-316. 10.1055\/s-2002-34469.","journal-title":"Am J Perinatol"},{"issue":"1","key":"787_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-2115(97)00129-2","volume":"76","author":"A Einarson","year":"1998","unstructured":"Einarson A, Koren G, Bergman U: Nausea and vomiting in pregnancy: a comparative European study. Eur J Obstet Gynecol Reprod Biol. 1998, 76 (1): 1-3. 10.1016\/S0301-2115(97)00129-2.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"787_CR10","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/j.1471-0528.2004.00236.x","volume":"111","author":"A Einarson","year":"2004","unstructured":"Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G: The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004, 111 (9): 940-943. 10.1111\/j.1471-0528.2004.00236.x.","journal-title":"BJOG"},{"issue":"300","key":"787_CR11","first-page":"215","volume":"54","author":"JP Fitzgerald","year":"1955","unstructured":"Fitzgerald JP: The effect of promethazine in nausea and vomiting of pregnancy. N Z Med J. 1955, 54 (300): 215-218.","journal-title":"N Z Med J"},{"issue":"4811","key":"787_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/bmj.1.4811.652","volume":"1","author":"S Lask","year":"1953","unstructured":"Lask S: Treatment of nausea and vomiting of pregnancy with antihistamines. Br Med J. 1953, 1 (4811): 652-653. 10.1136\/bmj.1.4811.652.","journal-title":"Br Med J"},{"issue":"5","key":"787_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0002-9378(96)70607-5","volume":"174","author":"CA Sullivan","year":"1996","unstructured":"Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC: A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol. 1996, 174 (5): 1565-1568. 10.1016\/S0002-9378(96)70607-5.","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"787_CR14","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","volume":"21","author":"PB Tremblay","year":"2003","unstructured":"Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J: Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003, 21 (11): 2147-2155. 10.1200\/JCO.2003.05.164.","journal-title":"J Clin Oncol"},{"issue":"5","key":"787_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.tpj.6500382","volume":"6","author":"T Sugai","year":"2006","unstructured":"Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T: The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J. 2006, 6 (5): 351-356.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"787_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/00016340903322727","volume":"89","author":"TW Goecke","year":"2010","unstructured":"Goecke TW, Ekici AB, Niesler B, Loehberg CR, Hammer C, Rappold G, Schanze D, Straub V, Altmann HH, Strissel P, et al: Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy. Acta Obstet Gynecol Scand. 2010, 89 (1): 7-14. 10.3109\/00016340903322727.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5 Suppl Underst","key":"787_CR17","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1067\/mob.2002.123054","volume":"186","author":"G Koren","year":"2002","unstructured":"Koren G, Boskovic R, Hard M, Maltepe C, Navioz Y, Einarson A: Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system for nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2002, 186 (5 Suppl Understanding): S228-S231.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"787_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/01443610500060651","volume":"25","author":"G Koren","year":"2005","unstructured":"Koren G, Piwko C, Ahn E, Boskovic R, Maltepe C, Einarson A, Navioz Y, Ungar WJ: Validation studies of the Pregnancy Unique-Quantification of Emesis (PUQE) scores. J Obstet Gynaecol. 2005, 25 (3): 241-244. 10.1080\/01443610500060651.","journal-title":"J Obstet Gynaecol"},{"issue":"Suppl 1","key":"787_CR19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/S0959-8049(05)80254-0","volume":"29A","author":"PL Andrews","year":"1993","unstructured":"Andrews PL, Bhandari P: The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer. 1993, 29A (Suppl 1): S11-S16.","journal-title":"Eur J Cancer"},{"issue":"12","key":"787_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJM199003223221204","volume":"322","author":"LX Cubeddu","year":"1990","unstructured":"Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990, 322 (12): 810-816. 10.1056\/NEJM199003223221204.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"787_CR21","first-page":"S15","volume":"25","author":"MB Tyers","year":"1989","unstructured":"Tyers MB, Bunce KT, Humphrey PP: Pharmacological and anti-emetic properties of ondansetron. Eur J Cancer Clin Oncol. 1989, 25 (Suppl 1): S15-S19.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"787_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1124\/mol.106.032144","volume":"72","author":"B Niesler","year":"2007","unstructured":"Niesler B, Walstab J, Combrink S, M\u00f6ller D, Kapeller J, Rietdorf J, B\u00f6nisch H, G\u00f6thert M, Rappold G, Br\u00fcss M: Characterization of the Novel Human Serotonin Receptor Subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol Pharmacol. 2007, 72 (1): 8-17. 10.1124\/mol.106.032144.","journal-title":"Mol Pharmacol"},{"issue":"6717","key":"787_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/16941","volume":"397","author":"PA Davies","year":"1999","unstructured":"Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF: The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999, 397 (6717): 359-363. 10.1038\/16941.","journal-title":"Nature"},{"issue":"2","key":"787_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1073\/pnas.0708454105","volume":"105","author":"K Krzywkowski","year":"2008","unstructured":"Krzywkowski K, Davies PA, Feinberg-Zadek PL, Br\u00e4uner-Osborne H, Jensen AA: High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci. 2008, 105 (2): 722-727. 10.1073\/pnas.0708454105.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"787_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/00008571-200108000-00002","volume":"11","author":"B Niesler","year":"2001","unstructured":"Niesler B, Flohr T, N\u00f6then MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA: Association between the 5\u2019 UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenet Genomics. 2001, 11 (6): 471-475.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"787_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00008571-200405000-00001","volume":"14","author":"R Kaiser","year":"2004","unstructured":"Kaiser R, Tremblay P-B, Sezer O, Possinger K, Roots I, Brockm\u00f6ller J: Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenet Genomics. 2004, 14 (5): 271-278.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"787_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.b.30070","volume":"131B","author":"B Frank","year":"2004","unstructured":"Frank B, Niesler B, N\u00f6then MM, Neidt H, Propping P, Bondy B, Rietschel M, Maier W, Albus M, Rappold G: Investigation of the human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet. 2004, 131B (1): 1-5. 10.1002\/ajmg.b.30070.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"3","key":"787_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/FPC.0b013e3282f51092","volume":"18","author":"C Meineke","year":"2008","unstructured":"Meineke C, Tzvetkov MV, Bokelmann K, Oetjen E, Hirsch-Ernst K, Kaiser R, Brockm\u00f6ller J: Functional characterization of a \u2212100_-102delAAG deletion-insertion polymorphism in the promoter region of the HTR3B gene. Pharmacogenet Genomics. 2008, 18 (3): 219-230. 10.1097\/FPC.0b013e3282f51092. 210.1097\/FPC.1090b1013e3282f51092","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"787_CR29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.alcohol.2008.09.005","volume":"43","author":"F Ducci","year":"2009","unstructured":"Ducci F, Enoch MA, Yuan Q, Shen PH, White KV, Hodgkinson C, Albaugh B, Virkkunen M, Goldman D: HTR3B is associated with alcoholism with antisocial behavior and alpha EEG power\u2013an intermediate phenotype for alcoholism and co-morbid behaviors. Alcohol. 2009, 43 (1): 73-84. 10.1016\/j.alcohol.2008.09.005.","journal-title":"Alcohol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2393-13-132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2393-13-132\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2393-13-132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2393-13-132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:24:26Z","timestamp":1630527866000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/1471-2393-13-132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1186\/1471-2393-13-132","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,20]]},"assertion":[{"value":"4 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"132"}}